Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2000 3
2001 2
2002 2
2003 6
2004 6
2005 4
2006 5
2007 3
2008 4
2009 3
2010 8
2011 3
2012 5
2013 27
2014 22
2015 23
2016 17
2017 16
2018 18
2019 22
2020 29
2021 22
2022 17
2023 29
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

269 results

Results by year

Filters applied: . Clear all
Page 1
Ospemifene efficacy and safety data in women with vulvovaginal atrophy.
Pup LD, Sánchez-Borrego R. Pup LD, et al. Gynecol Endocrinol. 2020 Jul;36(7):569-577. doi: 10.1080/09513590.2020.1757058. Epub 2020 Apr 24. Gynecol Endocrinol. 2020. PMID: 32329400 Review.
Some of the possible side effects included by FDA and EMA are hot flushes, headache, muscle spasms, vaginal bleeding and vaginal discharge. Ospemifene does not increase the incidence of endometrial cancer or hyperplasia. While the efficacy is comparable with that of estrog …
Some of the possible side effects included by FDA and EMA are hot flushes, headache, muscle spasms, vaginal bleeding and vaginal discharge. …
Ospemifene: A Novel Option for the Treatment of Vulvovaginal Atrophy.
Shin JJ, Kim SK, Lee JR, Suh CS. Shin JJ, et al. J Menopausal Med. 2017 Aug;23(2):79-84. doi: 10.6118/jmm.2017.23.2.79. Epub 2017 Aug 31. J Menopausal Med. 2017. PMID: 28951854 Free PMC article. Review.
In postmenopausal women with vulvovaginal atrophy, ospemifene significantly improves the structure and pH levels of the vagina, reducing dyspareunia. ...Studies evaluating the safety of treatment for up to 52 weeks have shown that ospemifene is a safe medication wit …
In postmenopausal women with vulvovaginal atrophy, ospemifene significantly improves the structure and pH levels of the vagina, reduc …
Ospemifene for vulvar and vaginal atrophy.
[No authors listed] [No authors listed] Drug Ther Bull. 2019 Jun;57(6):89-92. doi: 10.1136/dtb.2019.000011. Drug Ther Bull. 2019. PMID: 31142564 Review. No abstract available.
Ospemifene for the treatment of menopausal vaginal dryness, a symptom of the genitourinary syndrome of menopause.
Archer DF, Simon JA, Portman DJ, Goldstein SR, Goldstein I. Archer DF, et al. Expert Rev Endocrinol Metab. 2019 Sep;14(5):301-314. doi: 10.1080/17446651.2019.1657008. Epub 2019 Sep 17. Expert Rev Endocrinol Metab. 2019. PMID: 31526199 Review.
Areas covered: PubMed was searched from inception to March 2019 with keywords ospemifene and vulvar vaginal atrophy to review preclinical and clinical data describing the safety and efficacy of ospemifene for vaginal dryness and dyspareunia due to VVA. Covered topic …
Areas covered: PubMed was searched from inception to March 2019 with keywords ospemifene and vulvar vaginal atrophy to review preclin …
Ospemifene for vulvar and vaginal atrophy: an overview.
Palacios S. Palacios S. Drugs Context. 2020 Jul 1;9:2020-3-2. doi: 10.7573/dic.2020-3-2. eCollection 2020. Drugs Context. 2020. PMID: 32670378 Free PMC article.
As well as restoring vaginal health in symptomatic VVA, ospemifene may have collateral benefits of importance to postmenopausal women. In this Special Issue entitled "Treatment of Vulvar and Vaginal Atrophy: Clinical Experience with Ospemifene," illustrative case st …
As well as restoring vaginal health in symptomatic VVA, ospemifene may have collateral benefits of importance to postmenopausal women …
Ospemifene for the treatment of dyspareunia in postmenopausal women.
Paton DM. Paton DM. Drugs Today (Barc). 2014 May;50(5):357-64. doi: 10.1358/dot.2014.50.5.2134451. Drugs Today (Barc). 2014. PMID: 24918836 Review.
Ospemifene is a third-generation selective estrogen receptor modulator (SERM), structurally closely related to toremifene. ...Ospemifene had minimal effects on the endometrium of postmenopausal women. ...
Ospemifene is a third-generation selective estrogen receptor modulator (SERM), structurally closely related to toremifene. ...Ospe …
Ospemifene: a safe treatment of vaginal atrophy.
Del Pup L. Del Pup L. Eur Rev Med Pharmacol Sci. 2016 Sep;20(18):3934-3944. Eur Rev Med Pharmacol Sci. 2016. PMID: 27735020 Free article. Review.
Experimental and animal models suggest an inhibitory effect on the growth of malignant breast tissue. The available clinical data support ospemifene breast safety. CONCLUSIONS: Ospemifene relieves moderate to severe symptoms of vulvovaginal atrophy, like dryness, ir …
Experimental and animal models suggest an inhibitory effect on the growth of malignant breast tissue. The available clinical data support …
Ospemifene: first global approval.
Elkinson S, Yang LP. Elkinson S, et al. Drugs. 2013 May;73(6):605-12. doi: 10.1007/s40265-013-0046-y. Drugs. 2013. PMID: 23605694 Review.
Ospemifene (Osphena) is an oral selective estrogen receptor modulator (SERM), with tissue-specific estrogenic agonist/antagonist effects. ...This article summarizes the milestones in the development of ospemifene leading to this first approval for moderate to severe …
Ospemifene (Osphena) is an oral selective estrogen receptor modulator (SERM), with tissue-specific estrogenic agonist/antagonist effe …
Ospemifene in the treatment of vulvovaginal atrophy.
Barnes KN, Pearce EF, Yancey AM, Forinash AB. Barnes KN, et al. Ann Pharmacother. 2014 Jun;48(6):752-7. doi: 10.1177/1060028014526036. Epub 2014 Mar 10. Ann Pharmacother. 2014. PMID: 24615631 Review.
Search terms included ospemifene, FC-1271a, dyspareunia, vulvovaginal atrophy, and vaginal atrophy. ...Additionally, patients with a uterus still need to use a progestogen with ospemifene to reduce the risk of hyperplasia. CONCLUSIONS: Ospemifene has been eff …
Search terms included ospemifene, FC-1271a, dyspareunia, vulvovaginal atrophy, and vaginal atrophy. ...Additionally, patients with a …
Profile of ospemifene in the breast.
Berga SL. Berga SL. Reprod Sci. 2013 Oct;20(10):1130-6. doi: 10.1177/1933719113497290. Epub 2013 Aug 13. Reprod Sci. 2013. PMID: 23945733 Free article. Review.
Ospemifene, the first nonestrogen oral treatment for this indication, may provide an alternative to treatment with estrogen. ...Clinical trials, including 3 long-term studies assessing the overall safety of ospemifene, support that ospemifene is generally wel …
Ospemifene, the first nonestrogen oral treatment for this indication, may provide an alternative to treatment with estrogen. ...Clini …
269 results